NCT03048409

Brief Summary

A retrospective chart review to assess feeding tolerance in adults who had been switched from an intact protein formula to a peptide-based formula due to feeding intolerance in a complex continuing care facility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 9, 2017

Completed
6 months until next milestone

Study Start

First participant enrolled

July 24, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 2, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 2, 2018

Completed
Last Updated

July 12, 2019

Status Verified

July 1, 2019

Enrollment Period

1.2 years

First QC Date

February 7, 2017

Last Update Submit

July 11, 2019

Conditions

Outcome Measures

Primary Outcomes (7)

  • Feeding tolerance - Gastric residuals

    no change, tolerance improved, tolerance worsened

    Up to 30 days after formula switch

  • Feeding tolerance - gagging/retching

    no change, tolerance improved, tolerance worsened

    Up to 30 days after formula switch

  • Feeding tolerance - abdominal distension/gas

    no change, tolerance improved, tolerance worsened

    Up to 30 days after formula switch

  • Feeding tolerance - vomiting

    no change, tolerance improved, tolerance worsened

    Up to 30 days after formula switch

  • Feeding tolerance - stool consistency issues

    too hard, too loose

    Up to 30 days after formula switch

  • Volume of formula consumed in a day vs. goal

    documentation of feeding volume after switch as "less than," "about the same as," or "more than" feeding volume achieved before switch

    Up to 30 days after formula switch

  • Tube feeding interruptions

    Number of tube feeding interruptions

    Up to 30 days after formula switch

Secondary Outcomes (4)

  • Weight

    Prior to and up to 30 days following formula switch.

  • Medication use

    Prior to and up to 30 days following formula switch.

  • Caloric intake

    Up to 30 days after formula switch

  • Protein intake

    Up to 30 days after formula switch

Study Arms (1)

Enteral tube fed adults

Enteral formula

Other: Enteral Formula

Interventions

Enteral feeding with a peptide-based formula.

Enteral tube fed adults

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The population studied retrospectively will be adult patients in a chronic care facility dependent on enteral nutrition for 90% or more of their nutritional needs and meeting the inclusion/ exclusion criteria.

You may qualify if:

  • \> 18 years of age on admission to facility
  • Prescribed enteral nutrition with the goal to provide at least 90% of estimated daily calorie and protein requirements for ≥ 2 weeks prior to switch
  • Received enteral nutrition with an intact protein formula for a minimum of three days prior to a switch to a peptide-based formula
  • Have documentation of intolerance to an intact protein formula, followed by a switch in formula received to a peptide-based formula
  • Receiving a peptide-based formula formula for ≥ 2 weeks
  • Have documentation of an assessment of feeding tolerance following the switch
  • Formulas received must be indicated for use in adults.

You may not qualify if:

  • Abdominal surgery (within past 30 days prior to switch)
  • Having any infection, including upper respiratory, viral, gastroenteritis,wound infections, c difficile, at time of switch
  • Having documented cow's milk protein allergy at time of switch
  • Medical records lacking information on rationale for switch to a peptide-based formula and/or response to change (positive, neutral or negative).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bruyere Research Institute

Ottawa, Ontario, Canada

Location

Study Officials

  • Jean Chouinard, MD

    St Vincent's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2017

First Posted

February 9, 2017

Study Start

July 24, 2017

Primary Completion

October 2, 2018

Study Completion

October 2, 2018

Last Updated

July 12, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations